{"id":20927,"date":"2021-11-12T09:03:06","date_gmt":"2021-11-12T07:03:06","guid":{"rendered":"https:\/\/vilkaviskiovsb.lt\/?p=20927"},"modified":"2021-11-12T09:03:06","modified_gmt":"2021-11-12T07:03:06","slug":"lietuva-pritaria-bendram-vaistu-nuo-covid-19-ligos-pirkimui","status":"publish","type":"post","link":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/2021\/11\/12\/lietuva-pritaria-bendram-vaistu-nuo-covid-19-ligos-pirkimui\/","title":{"rendered":"Lietuva pritaria bendram vaist\u0173 nuo COVID-19 ligos pirkimui"},"content":{"rendered":"<p><strong>Lietuva pritaria bendroms Europos S\u0105jungos (ES) valstybi\u0173 nari\u0173 deryboms su farmacijos kompanijomis \u201eMerck Sharp &amp; Dohme\u201d ir \u201ePfizer\u201c, kurios pristat\u0117 rinkai vaistinius preparatus, skirtus gydyti COVID-19 liga sergan\u010dius pacientus. \u0160iuos vaistinius preparatus patvirtinus Europos vaist\u0173 agent\u016broje (EVA) ir juos \u012ftraukus \u012f S\u0105jungos registr\u0105, preparatai gal\u0117s bus vartojami ir Lietuvoje.<\/strong><\/p>\n<p>Spalio pabaigoje EVA prad\u0117jo vertinti duomenis apie farmacijos kompanijos \u201eMerck Sharp &amp; Dohme\u201c sukurt\u0105 antivirusin\u012f vaistin\u012f preparat\u0105 <em>Molnupiravir<\/em>, skirt\u0105 COVID-19 ligai gydyti. Jeigu EVA patvirtins, kad vaistas yra saugus ir veiksmingas, jis gal\u0117s b\u016bti u\u017eregistruotas ir prad\u0117tas tiekti \u012f ES rink\u0105.<\/p>\n<p>Kompanijos \u201ePfizer\u201c gaminamo antivirusinio preparato <em>Paxlovid <\/em>vertinimas gali b\u016bti prad\u0117tas artimiausiu metu.<\/p>\n<p>Pirmieji klinikiniai tyrimai rodo, kad vaistai <em>Molnupiravir <\/em>ir <em>Paxlovid<\/em>, skiriami COVID-19 liga jau susirgusiems pacientams, nuo 50 iki 90 proc. suma\u017eina rizik\u0105 susirgti sunkia \u0161ios ligos forma arba mirti.<\/p>\n<p>Kol laukiama daugiau tyrimais patvirtint\u0173 duomen\u0173 ir galutinio EVA sprendimo, Europos Komisija apklaus\u0117 valstybes nares, ar jos pageidaut\u0173 kartu der\u0117tis su gamintojais ir vaistus \u012fsigyti centralizuotu b\u016bdu. Lietuva tokiam si\u016blymui pritar\u0117, nes \u201ekalb\u0117jimas vienu balsu\u201c pad\u0117t\u0173 i\u0161sider\u0117ti geresnes pirkimo s\u0105lygas. Centralizuotas pirkimas pasiteisino ir \u012fsigyjant COVID-19 vakcinas: ES \u0161alys jas gavo vienos i\u0161 pirm\u0173j\u0173 ir u\u017esitikrino stabil\u0173 tiekim\u0105 keleriems metams.<\/p>\n<p>\u0160iuo metu Lietuvoje COVID-19 liga sergantiems pacientams gydyti yra naudojamas farmacijos kampanijos \u201eGilead\u201c gaminamas vaistinis preparatas \u201eVeklury\u201c (veiklioji med\u017eiaga <em>Remdesivir<\/em>), kuris taip pat yra perkamas centralizuotu b\u016bdu. \u0160iuo metu tai yra vienintelis vaistas nuo COVID-19 ligos, \u012ftrauktas \u012f ES vaistini\u0173 preparat\u0173 registr\u0105.<\/p>\n<p>Primename, kad vaistai yra skirti jau susirgusi\u0173 pacient\u0173 gydymui ir neapsaugo nuo u\u017esikr\u0117timo COVID-19 liga. \u017denkliai suma\u017einti rizik\u0105 u\u017esikr\u0117sti ir susirgti sunkia \u0161ios ligos forma padeda vakcinos, kuriomis pasiskiepyti gali kiekvienas Lietuvos gyventojas, registruodamasis internetu <a href=\"http:\/\/www.koronastop.lt\" target=\"_blank\" rel=\"noopener\">www.koronastop.lt<\/a> arba trumpuoju numeriu 1808.<\/p>\n<p><a href=\"https:\/\/sam.lrv.lt\/lt\/kontaktai-ziniasklaidai\" target=\"_blank\" rel=\"noopener\"><em>SAM Spaudos tarnyba<\/em><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lietuva pritaria bendroms Europos S\u0105jungos (ES) valstybi\u0173 nari\u0173 deryboms su farmacijos kompanijomis \u201eMerck Sharp &amp; Dohme\u201d ir \u201ePfizer\u201c, kurios pristat\u0117 rinkai vaistinius preparatus, skirtus gydyti COVID-19 liga sergan\u010dius pacientus. \u0160iuos vaistinius preparatus patvirtinus Europos vaist\u0173 agent\u016broje (EVA) ir juos \u012ftraukus \u012f S\u0105jungos registr\u0105, preparatai gal\u0117s bus vartojami ir Lietuvoje. Spalio pabaigoje EVA prad\u0117jo vertinti duomenis&hellip;<\/p>\n","protected":false},"author":3,"featured_media":20928,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[100],"tags":[],"class_list":["post-20927","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-del-covid-19","category-100","description-off"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7kWFe-5rx","jetpack_featured_media_url":"https:\/\/vilkaviskiovsb.lt\/wp-content\/uploads\/2021\/11\/19545_3f46b44fc8bab619232bb0001a666c2c.jpg","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts\/20927","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/comments?post=20927"}],"version-history":[{"count":1,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts\/20927\/revisions"}],"predecessor-version":[{"id":20929,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts\/20927\/revisions\/20929"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/media\/20928"}],"wp:attachment":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/media?parent=20927"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/categories?post=20927"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/tags?post=20927"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}